Should a patient be prescribed ticagrelor (Brilinta), clopidogrel (Plavix), and apixaban after a stroke?

No – This Triple Therapy Combination Is Not Appropriate After Stroke

A patient should NOT be on both Brilinta (ticagrelor) AND Plavix (clopidogrel) AND apixaban simultaneously after a stroke. This combination represents excessive antithrombotic therapy that dramatically increases bleeding risk without established benefit.

The Correct Approach: Choose ONE Strategy

For Acute Minor Stroke or High-Risk TIA (NIHSS 0-5, within 24 hours)

Dual antiplatelet therapy for 21-30 days ONLY:

• Aspirin PLUS clopidogrel (loading dose 300-600 mg clopidogrel, then 75 mg daily) 1
  • OR Aspirin PLUS ticagrelor (loading dose 180 mg, then 90 mg twice daily) 2, 3, 4
  • Duration: 21-30 days maximum, then switch to single antiplatelet 1
  • The POINT and CHANCE trials established this approach reduces recurrent stroke by approximately 15 per 1000 patients treated, with 5 additional major hemorrhages per 1000 1

After 21-30 days: Continue with single antiplatelet therapy (aspirin 75-162 mg daily OR clopidogrel 75 mg daily) indefinitely 1, 5

Critical Contraindications to Dual Antiplatelet Therapy

• Ticagrelor is contraindicated in patients with prior intracranial hemorrhage 6, 7
• Prasugrel is contraindicated in patients with prior stroke or TIA 6
• Dual antiplatelet therapy should NOT continue beyond 30 days for stroke prevention 1, 5, 8

When Anticoagulation (Apixaban) IS Indicated

Use apixaban (or another oral anticoagulant) INSTEAD of dual antiplatelets if:

• Atrial fibrillation is present (cardioembolic stroke) 9
• Mechanical heart valve
• Intracardiac thrombus

In these cases: Use oral anticoagulant ALONE or with single antiplatelet (aspirin), NOT dual antiplatelets 9

Why This Triple Combination Is Dangerous

Bleeding Risk Compounds Exponentially

1. Dual antiplatelet therapy alone increases major bleeding (0.9% vs 0.4% with aspirin alone) 1
2. Adding an anticoagulant to dual antiplatelets creates "triple therapy" – associated with major bleeding rates of 2-4% annually 9
3. No evidence supports combining two P2Y12 inhibitors (ticagrelor + clopidogrel) – this is pharmacologically redundant and dangerous

Guideline-Based Limitations

The 2016 Canadian AF guidelines address triple therapy only in the context of acute coronary syndrome with PCI in AF patients, recommending:

• OAC + clopidogrel (NOT ticagrelor) for up to 12 months
• Then OAC alone 9

This does NOT apply to stroke patients unless they have concurrent ACS requiring stenting.

Common Clinical Scenarios and Solutions

Scenario 1: Noncardioembolic Stroke (No AF)

• First 21-30 days: Aspirin + clopidogrel OR aspirin + ticagrelor
• After 30 days: Single antiplatelet (aspirin OR clopidogrel) indefinitely
• No role for apixaban

Scenario 2: Cardioembolic Stroke (AF Present)

• Apixaban alone (or other DOAC preferred over warfarin) 9
• No dual antiplatelet therapy
• Consider delaying anticoagulation 4-14 days after large stroke to reduce hemorrhagic transformation risk

Scenario 3: Stroke + Recent Coronary Stent + AF

• Most complex scenario requiring specialist consultation
• Generally: OAC + clopidogrel for limited duration (avoid ticagrelor in stroke patients)
• Minimize duration of dual therapy due to bleeding risk 9

Key Pitfalls to Avoid

1. Never combine two P2Y12 inhibitors (ticagrelor + clopidogrel) – they work via the same mechanism
2. Never continue dual antiplatelet therapy beyond 30 days for stroke prevention alone 1, 8
3. Never add antiplatelet therapy to anticoagulation unless there's a compelling indication (recent stent) and only for limited duration 9
4. Ticagrelor carries higher bleeding risk than clopidogrel (0.5% vs 0.1% major bleeding) and should be avoided in patients with prior intracranial hemorrhage 6, 4

Special Considerations

CYP2C19 Poor Metabolizers

• Clopidogrel requires CYP2C19 activation 10, 11
• Consider ticagrelor (direct-acting) if genetic testing shows poor metabolizer status 7, 10
• However, ticagrelor still contraindicated if prior intracranial hemorrhage

Aspirin Dosing with Ticagrelor

• Maximum aspirin dose with ticagrelor: 100 mg daily 7
• Higher aspirin doses reduce ticagrelor efficacy

The bottom line: This patient needs their medications rationalized immediately. Contact the prescribing physician to clarify the indication and consolidate to an evidence-based regimen – either dual antiplatelet therapy (if within 30 days of minor stroke) OR anticoagulation (if cardioembolic) OR single antiplatelet (if beyond 30 days), but never all three simultaneously.